Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates. In an interview with Targeted Oncology, Hua-Jay “Jeff” ...

Debi Weiss went to the doctor's office with what she thought were worsening flu symptoms, but got a very different diagnosis ...

Debi Weiss thought her fatigue and weakness was a seasonal illness, but her condition quickly worsened.

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), an oncology‑focused biopharmaceutical company and majority‑owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), ...

The pleural effusion that was initially drained recurred after two weeks but subsequently resolved on follow‑up imaging as part of the patient’s response to chemotherapy. Repeat LDH measurement was ...

Key opportunities in the B-cell inhibitors market for non-oncology diseases include the rising demand for targeted immunomodulatory therapies, driven by increasing autoimmune disorder prevalence.

BTK inhibitor monotherapy is foundational across several B-cell malignancies, with newer, more selective agents designed to preserve efficacy while improving tolerability relative to first-in-class ...

Giahan Tang, 24, opened about her cancer journey on TikTok where she's reached thousands of people ...

HealthDay News — Features that characterize presentation of vitreoretinal lymphoma are described in an article published online March 1 in Clinical & Experimental Ophthalmology.

Patient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...